120 related articles for article (PubMed ID: 20002500)
1. Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France.
Déti EK; Thiébaut R; Bonnet F; Lawson-Ayayi S; Dupon M; Neau D; Pellegrin JL; Malvy D; Tchamgoué S; Dabis F; Morlat P;
HIV Med; 2010 May; 11(5):308-17. PubMed ID: 20002500
[TBL] [Abstract][Full Text] [Related]
2. Chronic renal failure among HIV-1-infected patients.
Mocroft A; Kirk O; Gatell J; Reiss P; Gargalianos P; Zilmer K; Beniowski M; Viard JP; Staszewski S; Lundgren JD
AIDS; 2007 May; 21(9):1119-27. PubMed ID: 17502722
[TBL] [Abstract][Full Text] [Related]
3. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
Kamkuemah M; Kaplan R; Bekker LG; Little F; Myer L
Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
[TBL] [Abstract][Full Text] [Related]
4. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.
Mocroft A; Kirk O; Reiss P; De Wit S; Sedlacek D; Beniowski M; Gatell J; Phillips AN; Ledergerber B; Lundgren JD;
AIDS; 2010 Jul; 24(11):1667-78. PubMed ID: 20523203
[TBL] [Abstract][Full Text] [Related]
5. Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting.
Manosuthi W; Prasithsirikul W; Tantanathip P; Chimsuntorn S; Nilkamhang S; Sungkanuparph S
Southeast Asian J Trop Med Public Health; 2011 May; 42(3):643-50. PubMed ID: 21706942
[TBL] [Abstract][Full Text] [Related]
6. Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
Gérard L; Chazallon C; Taburet AM; Girard PM; Aboulker JP; Piketty C
Antivir Ther; 2007; 12(1):31-9. PubMed ID: 17503745
[TBL] [Abstract][Full Text] [Related]
7. Cystatin C and baseline renal function among HIV-infected persons in the SUN Study.
Overton ET; Patel P; Mondy K; Bush T; Conley L; Rhame F; Kojic EM; Hammer J; Henry K; Brooks JT;
AIDS Res Hum Retroviruses; 2012 Feb; 28(2):148-55. PubMed ID: 21480819
[TBL] [Abstract][Full Text] [Related]
8. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.
Crane HM; Kestenbaum B; Harrington RD; Kitahata MM
AIDS; 2007 Jul; 21(11):1431-9. PubMed ID: 17589189
[TBL] [Abstract][Full Text] [Related]
9. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
[TBL] [Abstract][Full Text] [Related]
10. Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study.
Guaraldi G; Roverato A; Giovanardi C; Ravera F; Squillace N; Orlando G; Cappelli G; Esposito R; Palella F
J Antimicrob Chemother; 2009 Feb; 63(2):374-9. PubMed ID: 19095683
[TBL] [Abstract][Full Text] [Related]
11. [Is assessment of kidney involvement in patients with essential hypertension satisfactory? General medical observation results in a national study (PHENOMEN)].
Mounier-Vehier C; Amah G; Duquenoy S; Fontaine P; Phan TM
Arch Mal Coeur Vaiss; 2003; 96(7-8):792-5. PubMed ID: 12945226
[TBL] [Abstract][Full Text] [Related]
12. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
[TBL] [Abstract][Full Text] [Related]
13. Low incidence of renal impairment observed in tenofovir-treated patients.
O'Donnell EP; Scarsi KK; Darin KM; Gerzenshtein L; Postelnick MJ; Palella FJ
J Antimicrob Chemother; 2011 May; 66(5):1120-6. PubMed ID: 21393145
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study.
Launay-Vacher V; Oudard S; Janus N; Gligorov J; Pourrat X; Rixe O; Morere JF; Beuzeboc P; Deray G;
Cancer; 2007 Sep; 110(6):1376-84. PubMed ID: 17634949
[TBL] [Abstract][Full Text] [Related]
15. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
[TBL] [Abstract][Full Text] [Related]
16. No change in calculated creatinine clearance after tenofovir initiation among Thai patients.
Gayet-Ageron A; Ananworanich J; Jupimai T; Chetchotisakd P; Prasithsirikul W; Ubolyam S; Le Braz M; Ruxrungtham K; Rooney JF; Hirschel B;
J Antimicrob Chemother; 2007 May; 59(5):1034-7. PubMed ID: 17376791
[TBL] [Abstract][Full Text] [Related]
17. The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity.
Boyd MA; Siangphoe U; Ruxrungtham K; Reiss P; Mahanontharit A; Lange JM; Phanuphak P; Cooper DA; Burger DM
J Antimicrob Chemother; 2006 Jun; 57(6):1161-7. PubMed ID: 16595641
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure.
Tordato F; Cozzi Lepri A; Cicconi P; De Luca A; Antinori A; Colangeli V; Castagna A; Nasta P; Ladisa N; Giacometti A; d'Arminio Monforte A; Gori A;
HIV Med; 2011 Jan; 12(1):4-13. PubMed ID: 20584091
[TBL] [Abstract][Full Text] [Related]
19. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.
Gallant JE; Parish MA; Keruly JC; Moore RD
Clin Infect Dis; 2005 Apr; 40(8):1194-8. PubMed ID: 15791522
[TBL] [Abstract][Full Text] [Related]
20. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study.
Antoniou T; Raboud J; Chirhin S; Yoong D; Govan V; Gough K; Rachlis A; Loutfy M
HIV Med; 2005 Jul; 6(4):284-90. PubMed ID: 16011534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
